Tanguy Y. Seiwert, MD, assistant professor of Medicine, University of Chicago Medicine, discusses the impact of immunotherapy agents as treatment of patients with head and neck cancer.

Immunotherapy agents are proving to be quite active in the field of head and neck cancer, with 20% to 25% response rates in patients with both HPV-positive and HPV-negative disease, Seiwert explains. However, the key benefit with PD-1 agents is survival, he says. In heavily pretreated patients, median survival is approximately 10 months with immunotherapy.

Given the exciting phase III data with nivolumab in head and neck cancer, Seiwert predicts that the FDA will approve both nivolumab and pembrolizumab in 2016.

View more from the 2016 Multidisciplinary Head and Neck Cancer Symposium

Conference

® Conference page includes a listing of all conferences covered by 

, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.


Head & Neck Cancers

The OncLive Head and Neck Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with head and neck cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research within head and neck cancer. 

Multidisciplinary Head and Neck Cancer Symposium

Tanguy Y. Seiwert, MD, assistant professor of Medicine, University of Chicago Medicine, discusses the impact of immunotherapy agents as treatment of patients with head and neck cancer. 

Dr. Seiwert on Immunotherapy in Head and Neck Cancer